ABSTRACT
Understanding cannabis-drug interactions is critical given regulatory changes that have increased access to and use of cannabis. Cannabidiol (CBD) and Δ-9-tetrahydrocannabinol (Δ9-THC), the most abundant phytocannabinoids, are in vitro reversible and time-dependent (CBD only) inhibitors of several cytochrome P450 (CYP) enzymes. Cannabis extracts were used to evaluate quantitatively potential pharmacokinetic cannabinoid-drug interactions in 18 healthy adults. Participant received, in a randomized cross-over manner (separated by ≥ 1 week), a brownie containing (i) no cannabis extract (ethanol/placebo), (ii) CBD-dominant cannabis extract (640 mg CBD + 20 mg Δ9-THC), or (iii) Δ9-THC-dominant cannabis extract (20 mg Δ9-THC and no CBD). After 30 minutes, participants consumed a cytochrome P450 (CYP) drug cocktail consisting of caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A). Plasma and urine samples were collected (0-24 hours). The CBD + Δ9-THC brownie inhibited CYP2C19 > CYP2C9 > CYP3A > CYP1A2 (but not CYP2D6) activity, as evidenced by an increase in the geometric mean ratio of probe drug area under the plasma concentration-time curve (AUC) relative to placebo (AUCGMR ) of omeprazole, losartan, midazolam, and caffeine by 207%, 77%, 56%, and 39%, respectively. In contrast, the Δ9-THC brownie did not inhibit any of the CYPs. The CBD + Δ9-THC brownie increased Δ9-THC AUCGMR by 161%, consistent with CBD inhibiting CYP2C9-mediated oral Δ9-THC clearance. Except for caffeine, these interactions were well-predicted by our physiologically-based pharmacokinetic model (within 26% of observed interactions). Results can be used to help guide dose adjustment of drugs co-consumed with cannabis products and the dose of CBD in cannabis products to reduce interaction risk with Δ9-THC.
Subject(s)
Cannabidiol , Cannabinoids , Cannabis , Hallucinogens , Humans , Adult , Cannabinoids/pharmacology , Cytochrome P-450 CYP1A2 , Cytochrome P-450 CYP2C19 , Caffeine/pharmacokinetics , Midazolam/pharmacokinetics , Cytochrome P-450 CYP3A , Losartan , Cytochrome P-450 CYP2C9 , Cytochrome P-450 Enzyme System , Cytochrome P-450 CYP2D6 , Drug Interactions , Omeprazole/pharmacokinetics , Plant Extracts/pharmacokinetics , Dronabinol/pharmacologyABSTRACT
Licorice, the roots and rhizomes of Glycyrrhiza glabra L., has been used as a medicinal herb, herbal adjuvant, and flavoring agent since ancient times. Recently, licorice extracts have become popular as dietary supplements used by females to alleviate menopausal symptoms. Exposure to licorice products containing high levels of glycyrrhizic acid can cause hypokalemia, but independent from this effect, preclinical data indicate that licorice can inhibit certain cytochrome P450 (P450) enzymes. To evaluate whether clinically relevant pharmacokinetic interactions of licorice with P450 enzymes exist, a phase 1 clinical investigation was carried out using a licorice extract depleted in glycyrrhizic acid (content <1%) and a cocktail containing caffeine, tolbutamide, alprazolam, and dextromethorphan, which are probe substrates for the enzymes CYP1A2, CYP2C9, CYP3A4/5, and CYP2D6, respectively. The botanically authenticated and chemically standardized extract of roots from G. glabra was consumed by 14 healthy menopausal and postmenopausal female participants twice daily for 2 weeks. The pharmacokinetics of each probe drug were evaluated immediately before and after supplementation with the licorice extract. Comparison of the average areas under the time-concentration curves (AUCs) for each probe substrate in serum showed no significant changes from licorice consumption, whereas time to reach peak concentration for caffeine and elimination half-life for tolbutamide showed small changes. According to the US Food and Drug Administration guidance, which is based on changes in the AUC of each probe substrate drug, the investigated licorice extract should not cause any clinically relevant pharmacokinetic interactions with respect to CYP3A4/5, CYP2C9, CYP2D6, or CYP1A2. SIGNIFICANCE STATEMENT: Despite generally-recognized-as-safe status, the licorice species Glycyrrhiza glabra has been associated with some toxicity. Preclinical studies suggest that G. glabra might cause pharmacokinetic drug interactions by inhibiting several cytochrome P450 enzymes. This phase 1 clinical study addressed these concerns by evaluating clinically relevant effects with respect to CYP3A4/5, CYP2C9, CYP2D6, and CYP1A2. These results showed that a standardized G. glabra extract did not cause any clinically relevant pharmacokinetic drug interactions with four major cytochrome P450 enzymes.
Subject(s)
Cytochrome P-450 CYP1A2 , Glycyrrhiza , Humans , Female , Cytochrome P-450 CYP2D6 , Caffeine/pharmacokinetics , Cytochrome P-450 CYP3A , Tolbutamide , Glycyrrhizic Acid , Cytochrome P-450 CYP2C9 , Cytochrome P-450 Enzyme System , Glycyrrhiza/chemistry , Dietary SupplementsABSTRACT
PURPOSE: The aim of the present study was to determine whether caffeine concentrations in human lens epithelial cells (LECs) achieved from acute peroral caffeine intake inhibit ultraviolet radiation-induced apoptosis in vitro. METHODS: Patients were planned for cataract surgery of both eyes with a caffeine abstinence of 2 weeks in total, starting 1 week before surgery of the first eye. The second eye was scheduled 1 week after the first eye. At the day of the second eye surgery, patients were given coffee containing 180 mg caffeine shortly before surgery. Lens capsules including LEC, harvested after capsulorhexis, were transferred to a cell culture dish and immediately exposed to close to threshold ultraviolet radiation (UVR). At 24 hr after UVR exposure, apoptotic LECs were analysed by TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining. RESULTS: TUNEL-positive cells were detected in UVR-exposed lens capsules both after caffeine intake and in controls. The mean difference in TUNEL-positive cells between caffeine intake and contralateral controls (no caffeine) resulted in a 95% CI 15.3 ± 10.4% (degrees of freedom: 16). CONCLUSION: Peroral caffeine consumption significantly decreased UVR-induced apoptosis in LEC supporting epidemiological findings that caffeine delays the onset of cataract.
Subject(s)
Caffeine/administration & dosage , Cataract/etiology , Epithelial Cells/radiation effects , Lens, Crystalline/radiation effects , Radiation Injuries/pathology , Ultraviolet Rays/adverse effects , Administration, Oral , Aged , Apoptosis/drug effects , Apoptosis/radiation effects , Caffeine/pharmacokinetics , Cataract/metabolism , Cataract/pathology , Central Nervous System Stimulants/administration & dosage , Central Nervous System Stimulants/pharmacokinetics , Epithelial Cells/drug effects , Epithelial Cells/pathology , Female , Follow-Up Studies , Humans , Lens, Crystalline/drug effects , Lens, Crystalline/pathology , Male , Pilot Projects , Prospective Studies , Radiation Injuries/complications , Radiation Injuries/metabolismABSTRACT
In vitro, esomeprazole is a time-dependent inhibitor of CYP2C19. Additionally, racemic omeprazole induces CYP1A2 and omeprazole and its metabolites inhibit CYP3A4 in vitro. In this 5-phase study, 10 healthy volunteers ingested 20 mg pantoprazole, 0.5 mg midazolam, and 50 mg caffeine as respective index substrates for CYP2C19, 3A4, and 1A2 before and 1, 25, 49 (pantoprazole only), and 73 hours after an 8-day pretreatment with 80 mg esomeprazole twice daily. The area under the plasma concentration-time curve (AUC) of R-pantoprazole increased 4.92-fold (90% confidence interval (CI) 3.55-6.82), 2.31-fold (90% CI 1.85-2.88), and 1.33-fold (90% CI 1.06-1.68) at the 1-hour, 25-hour, and 73-hour phases, respectively, consistent with a substantial and persistent inhibition of CYP2C19. The AUC of midazolam increased up to 1.44-fold (90% CI 1.22-1.72) and the paraxanthine/caffeine metabolic ratio up to 1.19-fold (90% CI 1.04-1.36), when the index substrates were taken 1 hour after esomeprazole. Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours. Pharmacokinetic simulation based on the observed concentrations of esomeprazole and its metabolites as well as their published CYP2C19 inhibitory constants was well in line with the observed changes in R-pantoprazole pharmacokinetics during the course of the study. Extrapolations assuming linear pharmacokinetics of esomeprazole suggested weak to moderate inhibition at 20 and 40 mg twice daily dosing. In conclusion, high-dose esomeprazole can cause strong inhibition of CYP2C19, but only weakly inhibits CYP3A4 and leads to minor induction of CYP1A2. The enzymatic activity of CYP2C19 recovers gradually in ~ 3-4 days after discontinuation of esomeprazole treatment.
Subject(s)
Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2C19 Inhibitors/pharmacology , Cytochrome P-450 CYP2C19/metabolism , Cytochrome P-450 CYP3A/metabolism , Esomeprazole/pharmacology , Administration, Oral , Caffeine/pharmacokinetics , Cross-Over Studies , Cytochrome P-450 CYP1A2 Inducers/pharmacology , Cytochrome P-450 CYP2C19/genetics , Cytochrome P-450 CYP2C19 Inhibitors/administration & dosage , Cytochrome P-450 CYP2C19 Inhibitors/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Esomeprazole/administration & dosage , Esomeprazole/pharmacokinetics , Female , Healthy Volunteers , Humans , Male , Midazolam/pharmacokinetics , Models, Biological , Pantoprazole/pharmacokinetics , Pharmacogenomic VariantsABSTRACT
Botanical dietary supplements produced from hops (Humulus lupulus) containing the chemopreventive compound xanthohumol and phytoestrogen 8-prenylnaringenin are used by women to manage menopausal symptoms. Because of the long half-lives of prenylated hop phenols and reports that they inhibit certain cytochrome P450 enzymes, a botanically authenticated and chemically standardized hop extract was tested for Phase I pharmacokinetic drug interactions. Sixteen peri- and postmenopausal women consumed the hop extract twice daily for 2 weeks, and the pharmacokinetics of tolbutamide, caffeine, dextromethorphan, and alprazolam were evaluated before and after supplementation as probe substrates for the enzymes CYP2C9, CYP1A2, CYP2D6, and CYP3A4/5, respectively. The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·µg/L pre-hop and 521.9 ± 36.1 h·µg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5. No enzyme inhibition was detected. According to FDA guidelines, this hop dietary supplement caused no clinically relevant pharmacokinetic interactions with respect to CYP2C9, CYP1A2, CYP2D6, or CYP3A4/5. The serum obtained after consumption of the hop extract was analyzed using ultra-high performance liquid chromatography-tandem mass spectrometry to confirm compliance. Abundant Phase II conjugates of the hop prenylated phenols were observed including monoglucuronides and monosulfates as well as previously unreported diglucuronides and sulfate-glucuronic acid diconjugates.
Subject(s)
Dietary Supplements/analysis , Herb-Drug Interactions , Humulus/chemistry , Perimenopause/drug effects , Plant Extracts/pharmacokinetics , Postmenopause/drug effects , Adult , Aged , Caffeine/pharmacokinetics , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Dextromethorphan/pharmacokinetics , Female , Humans , Middle Aged , Perimenopause/genetics , Perimenopause/metabolism , Plant Extracts/administration & dosage , Postmenopause/genetics , Postmenopause/metabolism , Tolbutamide/pharmacokineticsABSTRACT
INTRODUCTION: Caffeine and its metabolites have antioxidant activity, scavenging reactive oxygen species. The aim of our study was to measure caffeine concentrations in vitreous samples after peroral caffeine intake. METHODS: This prospective study included patients scheduled for 23-G pars plana vitrectomy with membrane peeling due to epiretinal membranes. The study was performed in two parts: in the first part, patients were recruited into three different groups: group A consisted of habitual coffee drinkers who agreed to drink coffee containing 180 mg caffeine 1 h before surgery (n = 10), group B consisted of habitual coffee drinkers who were not offered coffee before surgery (n = 5), and group C consisted of non-habitual coffee drinkers, forming the control group (n = 5). In the second part (group D) patients (habitual coffee drinkers) agreed to give additional blood serum samples for measurement of caffeine concentration. Harvested samples of vitreous (groups A-D), epiretinal membranes (groups A-C), and blood serum samples (group D) were examined for concentrations of caffeine with gas chromatography-mass spectrometry. RESULTS: Samples of 40 eyes of 40 patients were harvested. The concentrations of caffeine in the vitreous samples were 1,998 ± 967 ng/mL in group A and 1,108 ± 874 ng/mL in group B. In group C, caffeine concentrations were below 176 ng/mL in all vitreous samples. Both groups A and B had significantly higher concentrations of caffeine in the vitreous samples than group C (p < 0.002, p < 0.01, Mann-Whitney U test). Caffeine concentrations in epiretinal membranes were below the limits of detection. Correlation of caffeine concentrations between blood serum samples and vitreous samples in group D was high, with significantly higher caffeine concentrations in the blood serum. CONCLUSION: Coffee consumption leads to significant caffeine levels in the vitreous compared to patients in the control group, and caffeine concentrations in the vitreous showed a high correlation to blood serum concentrations of caffeine after peroral coffee consumption.
Subject(s)
Caffeine/pharmacokinetics , Coffee , Vitrectomy/methods , Vitreous Body/metabolism , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Vitreous Body/surgeryABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Propolis has been employed extensively in many cultures since ancient times as antiseptic, wound healing, anti-pyretic and others due to its biological and pharmacological properties, such as immunomodulatory, antitumor, anti-inflammatory, antioxidant, antibacterial, antiviral, antifungal, antiparasite activities. But despite its broad and traditional use, there is little knowledge about its potential interaction with prescription drugs. AIM OF THE STUDY: The main objective of this work was to study the potential herbal-drug interactions (HDIs) of EPP-AF® using an in vivo assay with a cocktail approach. MATERIALS AND METHODS: Subtherapeutic doses of caffeine, losartan, omeprazole, metoprolol, midazolam and fexofenadine were used. Sixteen healthy adult volunteers were investigated before and after exposure to orally administered 125 mg/8â¯h (375â¯mg/day) EPP-AF® for 15 days. Pharmacokinetic parameters were calculated based on plasma concentration versus time (AUC) curves. RESULTS: After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20â¯×â¯51.00â¯h.ng/mL), 8% (1085â¯×â¯999â¯h.ng/mL) and 13% (9.01â¯×â¯7.86â¯h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25. On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90â¯×â¯22.30â¯h.ng/mL) and 14% (1.25â¯×â¯1.43â¯h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25. Changes in pharmacokinetics of metoprolol or its metabolite α-hydroxymetoprolol were not statistically significant and their 90% CIs were within the equivalence range of 0.80-1.25. CONCLUSIONS: In conclusion, our study shows that EPP-AF® does not clinically change CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A activities, once, despite statistical significant, the magnitude of the changes in AUC values after EPP-AF® were all below 20% and therefore may be considered safe regarding potential interactions involving these enzymes. Besides, to the best of our knowledge this is the first study to assess potential HDIs with propolis.
Subject(s)
Caffeine/pharmacokinetics , Losartan/pharmacokinetics , Metoprolol/pharmacokinetics , Midazolam/pharmacokinetics , Omeprazole/pharmacokinetics , Propolis , Terfenadine/analogs & derivatives , ATP Binding Cassette Transporter, Subfamily B/metabolism , Adult , Caffeine/blood , Cross-Over Studies , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Female , Humans , Losartan/blood , Male , Metoprolol/blood , Midazolam/blood , Omeprazole/blood , Terfenadine/blood , Terfenadine/pharmacokineticsABSTRACT
Background Hibiscus sabdariffa beverage (HSB) is widely consumed as a medicinal herb and sometimes used concomitantly with drugs. This study evaluated the in vitro inhibitory potential of the aqueous extract of H. sabdariffa calyces (AEHS) on selected cytochrome P450 (CYP) isozymes and the effect of HSB on the pharmacokinetics of caffeine in vivo. Methods In vitro inhibitions of eight major CYP isozymes by AEHS were estimated by monitoring CYP-specific model reactions of 10 CYP probe substrates using N-in-one assay method. Subsequently, an open, randomized, two-period crossover design was used to evaluate the effect of HSB on the pharmacokinetics of single-dose 200 mg caffeine in six healthy human volunteers. Blood samples were obtained at specific times over a 24 h period. Probe drugs and metabolites were analyzed in their respective matrices with ultra-performance liquid chromatography/mass spectrometer/mass spectrometer and reversed-phase high-performance liquid chromatography/ultraviolet detection. Results The H. sabdariffa aqueous extract weakly inhibited the selected CYP isozymes in vitro, with IC50 of >100 µgmL-1 in the order of CYP1A2 > CYP2C8 > CYP2B6 >> CYP2D6 > CYP2C19 > CYP3A4 > CYP2A6 > CYP2C9. HSB decreased terminal t1/2 and Tmax of caffeine by 13.6% and 13.0%, respectively, and increased Cmax by 10.3%. Point estimates of primary pharmacokinetic endpoints, Cmax = 1.142 (90% confidence interval (CI) = 0.882, 1.480) and AUC0-∞ = 0.992 (90% CI = 0.745, 1.320), were outside the 90% CI of 0.8-1.25 bioequivalence limits. Conclusion The aqueous extract of H. sabdariffa weakly inhibited eight CYP isozymes in vitro, but HSB modified the exposure to caffeine in human. Caution should be exercised in administering HSB with caffeine or similar substrates of CYP1A2 until more clinical data are available.
Subject(s)
Caffeine/pharmacokinetics , Cytochrome P-450 Enzyme System/blood , Herb-Drug Interactions , Hibiscus/chemistry , Plant Extracts/pharmacology , Caffeine/blood , Cross-Over Studies , Healthy Volunteers , Humans , Isoenzymes/blood , Substrate SpecificityABSTRACT
SCOPE: Dietary polyphenols may protect against breast cancer. However, it is unknown whether polyphenols reach human malignant breast tumors in molecular forms and(or) at concentrations likely to act against cancer. METHODS AND RESULTS: Ninteen breast cancer patients consumed three capsules daily from biopsy-confirmed diagnosis to surgery (6 ± 2 days). The capsules contained pomegranate, orange, lemon, olive, cocoa, and grapeseed extracts plus resveratrol, providing 37 different phenolics (473.7 mg), theobromine and caffeine (19.7 mg). A total of 101 metabolites are identified in urine, 69 in plasma, 39 in normal (NT), and 33 in malignant (MT) tissues by UPLC-ESI-QTOF-MS. Eight control patients did not consume extracts. Phenolic-derived metabolites in MT and NT are mainly glucuronidated and(or) sulfated. Some representative metabolites detected in MT (median and range, pmol g-1 ) are urolithin-A-3-O-glucuronide (26.2; 3.2-66.5), 2,5-dihydroxybenzoic acid (40.2; 27.7-52.2), resveratrol-3-O-sulfate (86.4; 7.8-224.4), dihydroresveratrol-3-O-glucuronide (109.9; 10.3-229.4), and theobromine (715.0; 153.9-3,216). Metabolites, as detected in breast tissues, do not exert antiproliferative or estrogenic/antiestrogenic activities in MCF-7 breast cancer cells. CONCLUSION: This is the first study that describes the metabolic profiling of dietary phenolics and methylxanthines in MT and NT comprehensively. Although phase-II conjugation might hamper a direct anticancer activity, long-term tumor-senescent chemoprevention cannot be discarded.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Breast Neoplasms/diet therapy , Polyphenols/pharmacokinetics , Xanthines/pharmacokinetics , Adult , Aged , Breast Neoplasms/metabolism , Breast Neoplasms/surgery , Breast Neoplasms, Male/diet therapy , Breast Neoplasms, Male/metabolism , Breast Neoplasms, Male/surgery , Caffeine/pharmacokinetics , Cell Proliferation/drug effects , Dietary Supplements , Female , Humans , MCF-7 Cells , Male , Mammary Glands, Human/drug effects , Mammary Glands, Human/metabolism , Middle Aged , Theobromine/pharmacokineticsABSTRACT
The caffeine metabolic ratio is an established marker for cytochrome P450 (CYP) 1A2 activity. Optimal sample size calculation for clinical pharmacokinetic xenobiotic-caffeine interaction studies requires robust estimates of interindividual and intraindividual variation in this ratio. Compared with interindividual variation, factors contributing to intraindividual variation are less defined. An exploratory analysis involving healthy nonsmoking non-naïve caffeine drinkers (1-3 cups/day; 12 men, 12 women) administered caffeine (160 mg) on five occasions evaluated the effects of CYP1A2 induction status (based on genotype) and other factors on intraindividual variation in CYP1A2 activity. Results were compared with those from previous studies. Regardless of whether a hyperinducer (CYP1A2*1A/*1F or CYP1A2*1F/*1F) or normal metabolizer (CYP1A2*1A/*1A, CYP1A2*1C/*1F, or CYP1A2*1C*1F/*1C*1F), sex, age, oral contraceptive use by women, and smoking status, intraindividual variation was ≤30%. A value of 30% is proposed for optimal design of pharmacokinetic xenobiotic-caffeine interaction studies. Prospective studies are needed for confirmation.
Subject(s)
Biological Variation, Individual , Caffeine/pharmacokinetics , Coffee/metabolism , Cytochrome P-450 CYP1A2/genetics , Adolescent , Adult , Alleles , Caffeine/administration & dosage , Clinical Trials, Phase I as Topic , Coffee/chemistry , Cytochrome P-450 CYP1A2/metabolism , Female , Food-Drug Interactions , Genotyping Techniques , Healthy Volunteers , Humans , Male , Polymorphism, Genetic , Prospective Studies , Research Design , Young AdultABSTRACT
Shuanghuanglian Injection (SHLI), one of the most popular herbal prescription in China, has been commonly used to treat pneumonia, tonsillitis, and other respiratory diseases caused by bacterium and virus. This study is to investigate the effects of SHLI on the activities of Cytochrome P450 (CYP) 1A2, 2C11, 2D1 and 3A1/2 in rats. Sixteen rats were randomly divided into two groups (SHLI-treated and blank control). They were administered SHLI or physiological saline for consecutive seven days. On day eight, 16 animals were administrated cocktail drugs as probe substrates of the four CYP in vivo. In addition, other four probe drugs were added, respectively, into incubation systems of rat liver microsomes (RLM) to assess the effects of SHLI on the four CYP isoforms in vitro. SHLI exhibited an inductive effect on CYP2C11 in vivo by decreasing Cmax, t1/2 and AUC0-∞ of tolbutamide, while the main pharmacokinetic parameters of caffeine, metoprolol and dapsone have no significant changes. In vitro study, SHLI showed no significant effects on the activities of CYP1A2, 2D1 and 3A1/2, but increasing the metabolism of tolbutamide in RLM. SHLI induced the activities of CYP2C11, but had no significant effects on the activities of CYP1A2, CYP2D1 and CYP3A1/2 in rats.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/pharmacology , Injections , Animals , Caffeine/blood , Caffeine/pharmacokinetics , Caffeine/pharmacology , Calibration , Dapsone/blood , Dapsone/pharmacokinetics , Limit of Detection , Male , Metabolome , Metoprolol/blood , Metoprolol/pharmacokinetics , Rats, Wistar , Reproducibility of Results , Time Factors , Tolbutamide/blood , Tolbutamide/pharmacokineticsABSTRACT
Purpose: Red ginseng is one of the world's most popular herbal medicines; it exhibits a wide range of pharmacologic activities and is often co-ingested with other herbal and conventional medicines. This open-label, randomized, 3-period study investigated the in vivo herb-drug interaction potential for red ginseng extract with cytochrome P-450 (CYP) enzymes and organic anion-transporting polypeptide (OATP) 1B1. METHODS: Fifteen healthy male volunteers (22-28 years; 57.1-80.8 kg) were administered a single dose of cocktail probe substrates (caffeine 100 mg, losartan 50 mg, omeprazole 20 mg, dextromethorphan 30 mg, midazolam 2 mg, and pitavastatin 2 mg) and single or multiple doses of red ginseng extract for 15 days. FINDINGS: The pharmacokinetic profiles of the probe substrates and metabolites after single- or multiple-dose administration of red ginseng extracts were comparable to the corresponding profiles of the control group. The geometric mean ratio of AUC0-t and 90% CIs for the probe substrate drugs between the control and multiple doses of red ginseng for 15 days were within 0.8 to 1.25 (CYP2C9, CYP3A4, and OATP1B1 probe substrates) or slightly higher (CYP1A2, CYP2C19, and CYP2D6 probe substrates). Additional assessments of the in vitro drug interaction potential of red ginseng extracts and the ginsenoside Rb1 on drug-metabolizing enzymes and transporters using human liver microsomes, cryopreserved human hepatocytes, and transporter-overexpressed cells were negative. IMPLICATIONS: Red ginseng poses minimal risks for clinically relevant CYP- or OATP-mediated drug interactions and is well tolerated. Clinical Research Information Service registry no.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Panax , Plant Preparations/pharmacology , Adult , Caffeine/metabolism , Caffeine/pharmacokinetics , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2C19/metabolism , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 CYP3A/metabolism , Dextromethorphan/metabolism , Dextromethorphan/pharmacokinetics , Drug Interactions , Humans , Liver-Specific Organic Anion Transporter 1/metabolism , Losartan/metabolism , Losartan/pharmacokinetics , Male , Midazolam/metabolism , Midazolam/pharmacokinetics , Omeprazole/metabolism , Omeprazole/pharmacokinetics , Random Allocation , Young AdultABSTRACT
Kidney stone disease is a global health care problem, with a high recurrence rate after stone removal. It is thus crucial to develop effective strategies to prevent the formation of new or recurrent stones. Caffeine is one of the main components in caffeinated beverages worldwide (i.e., coffee, tea, soft drinks, and energy drinks). Previous retrospective and prospective studies have reported contradictory effects of caffeine on kidney stone risk. Although it has a diuretic effect on enhancing urinary output, it may slightly increase the stone risk index. However, 3 large cohorts have suggested a preventive role of caffeine in kidney stone disease. In addition, a recent in vitro study has addressed relevant mechanisms underlying the preventive role of caffeine against stone pathogenesis. This review summarizes the relevant data from previous evidence and discusses the association between caffeine consumption and kidney stone risk reduction.
Subject(s)
Caffeine/administration & dosage , Caffeine/adverse effects , Kidney Calculi/epidemiology , Kidney Calculi/prevention & control , Beverages , Caffeine/pharmacokinetics , Carbonated Beverages , Coffee , Diet , Diuretics , Dose-Response Relationship, Drug , Energy Drinks , Humans , Kidney/drug effects , Prospective Studies , Recurrence , Retrospective Studies , Risk Factors , TeaABSTRACT
Coffee's long-term effect on cognitive function remains unclear with studies suggesting both benefits and adverse effects. We used Mendelian randomization to investigate the causal relationship between habitual coffee consumption and cognitive function in mid- to later life. This included up to 415,530 participants and 300,760 coffee drinkers from 10 meta-analysed European ancestry cohorts. In each cohort, composite cognitive scores that capture global cognition and memory were computed using available tests. A genetic score derived using CYP1A1/2 (rs2472297) and AHR (rs6968865) was chosen as a proxy for habitual coffee consumption. Null associations were observed when examining the associations of the genetic score with global and memory cognition (ß = -0.0007, 95% C.I. -0.009 to 0.008, P = 0.87; ß = -0.001, 95% C.I. -0.005 to 0.002, P = 0.51, respectively), with high consistency between studies (Pheterogeneity > 0.4 for both). Domain specific analyses using available cognitive measures in the UK Biobank also did not support effects by habitual coffee intake for reaction time, pairs matching, reasoning or prospective memory (P ≥ 0.05 for all). Despite the power to detect very small effects, our meta-analysis provided no evidence for causal long-term effects of habitual coffee consumption on global cognition or memory.
Subject(s)
Basic Helix-Loop-Helix Transcription Factors/genetics , Caffeine/pharmacology , Cognition/drug effects , Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 CYP1A2/genetics , Memory/drug effects , Receptors, Aryl Hydrocarbon/genetics , Biological Specimen Banks , Caffeine/pharmacokinetics , Coffee , Cohort Studies , Europe/epidemiology , Female , Genetic Variation , Humans , Male , Mendelian Randomization Analysis , Polymorphism, Single Nucleotide , Risk Factors , United KingdomABSTRACT
Coffee is a primary dietary source of the chlorogenic acids (CGAs) of phenolic compounds. Coffee contains caffeine and other phytonutrients, including CGAs. Caffeine on its own has been well characterized and descried pharmacokinetically in the literature, less so for CGAs. The purpose of this double-blind crossover study was to determine the comparative pharmacokinetics of CGAs with caffeine (natural extract) with synthetic caffeine (US Pharmacopeia [USP] standard). Sixteen healthy male subjects were randomly assigned to take 1 dose of product 1, 60 mg of botanically sourced caffeine from 480 mg of green coffee bean extract, or product 2, 60 mg of synthetic USP caffeine, with 5 days between. Blood analysis was done to determine the levels of CGA compounds, more specifically 3-, 4-, and 5-caffeoylquinic acid (CQA), and serum caffeine. The natural caffeine extract exhibited mean peak concentrations (Cmax ) of 3-CQA (11.4 ng/mL), 4-CQA (6.84 ng/mL), and 5-CQA (7.20 ng/mL). The mean systemic 4-hour exposure (AUC0-4 h ) was 3-CQA (27.3 ng·h/mL), 4-CQA (16.1 ng·h/mL), and 5-CQA (15.7 ng·h/mL). The median tmax was 3-CQA (1.00 hour), 4-CQA (1.00 hour), and 5-CQA (1.50 hours). The tmax of caffeine was 0.75 hours (natural extract) and 0.63 hours (synthetic caffeine). Cmax and AUC0-4 h of serum caffeine were statistically equivalent between products. The geometric least-squares mean ratios (GMRs) of Cmax and AUC0-4 h of caffeine were 97.77% (natural extract) and 98.33% (synthetic caffeine). It would appear that CGA compounds from the natural caffeine extract are bioavailable, and 3-CGA may be the compound most absorbed. In addition, caffeine sourced from natural extract versus synthetic were statistically similar for pharmacokinetic parameters. There were no adverse events or safety concerns.
Subject(s)
Caffeine/chemical synthesis , Caffeine/pharmacokinetics , Coffee/chemistry , Plant Extracts/pharmacokinetics , Caffeine/blood , Caffeine/isolation & purification , Central Nervous System Stimulants/blood , Central Nervous System Stimulants/pharmacokinetics , Chlorogenic Acid/blood , Cross-Over Studies , Double-Blind Method , Healthy Volunteers , Humans , Male , Plant Extracts/chemistry , Seeds/chemistryABSTRACT
Purpose: To determine the pharmacokinetics of perorally administered caffeine, a widely consumed and potent dietary antioxidant, in the anterior lens capsule and lens epithelial cells, a crucial cell monolayer for cataract development. Methods: Bilateral cataract patients were scheduled for cataract surgery with a caffeine abstinence of 1 week before surgery of each eye. At the day of surgery of the second eye patients were administered no drink (0-mg group) or coffee with 60-, 120-, or 180-mg caffeine. After capsulorhexis the lens capsule including lens epithelial cells was transferred to a test tube for analysis of caffeine concentration by gas chromatography-mass spectrometry (GC-MS/MS). Results: Coffee consumption significantly (P < 0.05) increased caffeine levels of the lens capsule/epithelium in the 60-, 120-, and 180-mg group. Caffeine concentrations (caffeine ng/lens capsule/epithelium) measured as difference between 1st and 2nd eye were -0.52 ± 1.16 (0-mg group, n = 7), 1.88 ± 2.02 (60-mg group, n = 8), 2.09 ± 0.67 (120-mg group, n = 9), and 3.68 ± 1.86 (180-mg group, n = 9). The increase constant of caffeine in a linear regression model was estimated as a 95% CI 0.02 ± 0.0046 (degrees of freedom; 25; r = 0.85). Conclusions: Peroral intake of coffee significantly increased caffeine concentrations in the lens capsule and lens epithelial cells in a dose-dependent manner. This information is important for further investigations on preventing cataract.
Subject(s)
Anterior Capsule of the Lens/metabolism , Caffeine/pharmacokinetics , Central Nervous System Stimulants/pharmacokinetics , Epithelial Cells/metabolism , Lens, Crystalline/cytology , Administration, Oral , Aged , Cataract/complications , Cataract Extraction , Coffee , Female , Gas Chromatography-Mass Spectrometry , Humans , Male , Pilot Projects , Tandem Mass Spectrometry , Tissue DistributionABSTRACT
Most individuals adjust their caffeine intake according to the objective and subjective effects induced by the methylxanthine. However, to reach the desired effects, the quantity of caffeine consumed varies largely among individuals. It has been known for decades that the metabolism, clearance, and pharmacokinetics of caffeine is affected by many factors such as age, sex and hormones, liver disease, obesity, smoking, and diet. Caffeine also interacts with many medications. All these factors will be reviewed in the present document and discussed in light of the most recent data concerning the genetic variability affecting caffeine levels and effects at the pharmacokinetic and pharmacodynamic levels that both critically drive the level of caffeine consumption. The pharmacokinetics of caffeine are highly variable among individuals due to a polymorphism at the level of the CYP1A2 isoform of cytochrome P450, which metabolizes 95% of the caffeine ingested. Moreover there is a polymorphism at the level of another critical enzyme, N-acetyltransferase 2. At the pharmacodynamic level, there are several polymorphisms at the main brain target of caffeine, the adenosine A2A receptor or ADORA2. Genetic studies, including genome-wide association studies, identified several loci critically involved in caffeine consumption and its consequences on sleep, anxiety, and potentially in neurodegenerative and psychiatric diseases. We start reaching a better picture on how a multiplicity of biologic mechanisms seems to drive the levels of caffeine consumption, although much more knowledge is still required to understand caffeine consumption and effects on body functions.
Subject(s)
Biological Variation, Individual , Caffeine/metabolism , Coffee/metabolism , Cytochrome P-450 Enzyme System/metabolism , Polymorphism, Genetic , Animals , Caffeine/pharmacokinetics , Coffee/genetics , Cytochrome P-450 Enzyme System/genetics , Drug Interactions , Humans , Pharmaceutical Preparations/metabolism , Tissue DistributionABSTRACT
Lipid based formulations, endowed of long term stability as a result of the formation of lamellar liquid crystals, were prepared using the natural lipids lecithin and glycerol trioleate in water, and characterized using optical microscopy, SAXRD and NMR. The formulations, designed as possible carriers for lysozyme and caffeine, were evaluated for structural features and stability after the loading of the guest molecules. Release experiments were performed at 37⯰C using the PBS medium. No burst release was observed either for lysozyme or caffeine. Although lysozyme released from the lipid formulations does not fully retain its biological activity, the investigated liquid crystal stabilized formulations display a promising potential as drug and cosmetic carriers for topical applications, due to their high biocompatibility.
Subject(s)
Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Lipids/chemistry , Liquid Crystals/chemistry , Caffeine/chemistry , Caffeine/pharmacokinetics , Central Nervous System Stimulants/chemistry , Central Nervous System Stimulants/pharmacokinetics , Delayed-Action Preparations/pharmacokinetics , Drug Compounding/methods , Drug Liberation , Hydrophobic and Hydrophilic Interactions , Lecithins/chemistry , Magnetic Resonance Spectroscopy , Muramidase/chemistry , Muramidase/pharmacokinetics , Scattering, Small Angle , Triolein/chemistry , X-Ray DiffractionABSTRACT
La cafeína es una de las sustancias psicoactivas más consumidas en todo el mundo; se encuentra presente en chocolates, bebidas colas, bebidas energéticas, café e infusiones, actúa sobre el sistema nervioso central. Su consumo elevado puede provocar irritabilidad, palpitaciones, temblores y convulsiones. El objetivo del trabajo ha sido determinar y comparar las ID de cafeína de niños de etapa escolar y estudiantes de educación superior de San Salvador de Jujuy, para establecer el nivel de exposición, a partir de la cuantificación de cafeína en los alimentos más consumidos en ambos grupos. Se realizaron 240 encuestas en 6 escuelas primarias y 4 instituciones de nivel superior, para conocer la ingesta de cafeína y las principales fuentes de cafeína. Se realizó la determinación de cafeína en bebidas de cola, de chocolate, e infusiones (té, mate, mate cebado y café) de las marcas más consumidas y disponibles en los supermercados, la extracción se realizó con cloroformo y la determinación analítica mediante espectrofotométrica U.V - visible." Las ingestas diarias se calcularon, considerando los volúmenes de bebidas e infusiones consumidas, los pesos corporales de cada niño y joven-adulto encuestado y la concentración de cafeína aportados por los alimentos. Las bebidas colas presentaron concentraciones de cafeína entre 0,03 y 0,19 mg/L; las infusiones de 0,15-0,67 "mg/L"; las chocolatadas 0,03-0,06"mg/L"; el mate cebado 0,67"mg/L"; bebidas energéticas 0,35"mg/L". Las IDEt promedio en mg/día en las niñas fueron de 321,71"mg/L"; en los niños de 314,7"mg/L"; en jóvenes adultas de 420 "mg/L" y jóvenes adultos de 379,8"mg/L". El promedio de IDEt (mg/Kg pc/día) para niños fue de 7,07 "mg/L" y para adultos de 6,4"mg/L". Se concluye que la población infantil presenta una ID de cafeína mayor a los adultos y los posiciona como consumidores moderados a altos de cafeína. El té fue el principal contribuyente de cafeína en ambas poblaciones
Caffeine is one of the most consumed psychoactive substances in the world; It is present in chocolates, cola drinks, energy drinks, coffee and infusions, acts on the central nervous system. Its high consumption can cause irritability, palpitations, tremors and convulsions. The aim of this study was to determine and compare the caffeine ID of school children and higher education students of San Salvador de Jujuy, to establish the level of exposure, from the quantification of caffeine in the foods most consumed in both groups. 240 surveys were conducted in 6 primary schools and 4 institutions of higher level, to know the intake of caffeine and the main sources of caffeine. The determination of caffeine in cola beverages, chocolate, and infusions (tea, mate, mate cebado and coffee) of the brands most consumed and available in supermarkets, the extraction was made with chloroform and the analytical determination by UV spectrophotometry - visible. ".The daily intakes were calculated, taking into account the volumes of beverages and infusions consumed, the body weights of each child and young adult surveyed and the concentration of caffeine provided by the food. The cola drinks presented caffeine concentrations between 0.03 and 0.19 mg / L; the infusions of 0.15-0.67 "mg / L"; chocolate bars 0.03-0.06 "mg / L"; the primed mate 0.67 "mg / L"; energy drinks 0.35 "mg / L". The mean IDEt in mg / day in girls was 321.71 "mg / L"; in children 314.7 "mg / L"; in young adults of 420 "mg / L" and young adults of 379.8 "mg / L". The average IDEt (mg / Kg pc / day) for children was 7.07 "mg / L" and for adults 6.4 "mg / L". It is concluded that the infant population has a higher caffeine ID than adults and positions them as moderate to high caffeine consumers. Tea was the main contributor of caffeine in both populations
Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Caffeine/administration & dosage , Drinking , Behavior, Addictive/epidemiology , Students/statistics & numerical data , Argentina/epidemiology , Caffeine/pharmacokinetics , Diet Surveys/statistics & numerical data , Coffee , Tea , Carbonated Beverages/statistics & numerical data , Energy Drinks/statistics & numerical dataABSTRACT
OBJECTIVE: Evaluate whether saliva could be a useful alternative to serum for routine therapeutic drug monitoring of caffeine in preterm infants using the enzyme multiplied immunoassay technique (EMIT) assay. METHODS: We conducted a prospective study including preterm infants (less than 34 weeks' amenorrhea) admitted to the intensive care and neonatal medicine department. All infants received 5, 10, 15, 20 and 25mg/kg/day of citrate caffeine intravenously from the first to the fifth day of birth, respectively. For each patient, two concomitant blood and saliva samples corresponding to the trough concentrations were collected 24hours after each caffeine dose. The caffeine concentrations were determined using the EMIT®2000 caffeine assay. RESULTS: Thirteen preterm infants were included. The saliva and the serum caffeine concentration increased proportionally to the administered dose. Saliva and serum kinetics were comparable and the saliva caffeine concentrations were correlated to the serum ones (r2=0.76). CONCLUSION: Saliva caffeine monitoring by EMIT is a valid, useful and safe alternative to serum in preterm infants.